Khan Simran, Bhake Arvind, Sagar Shakti
Pathology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus. 2024 Jul 18;16(7):e64872. doi: 10.7759/cureus.64872. eCollection 2024 Jul.
The BRAFV600E mutation has been extensively studied in various cancers, but its role in breast lesions remains less understood. Immunohistochemistry (IHC) has emerged as a valuable tool for detecting BRAFV600E expression in breast tissue, aiding in diagnosis and prognosis. This comprehensive review examines the significance of BRAFV600E IHC in breast lesions, encompassing its frequency, association with clinicopathological features, and potential clinical implications. We summarize key findings, emphasizing their utility in diagnosis, prognosis prediction, and treatment response assessment. Additionally, we discuss implications for clinical practice, highlighting the need for integrating BRAFV600E IHC into diagnostic algorithms. Recommendations for future research include larger-scale studies to validate findings, optimize detection techniques, and explore therapeutic interventions targeting BRAFV600E in breast cancer. This review contributes to understanding the molecular landscape of breast lesions and informs clinical decision-making in their management.
BRAFV600E突变已在多种癌症中得到广泛研究,但其在乳腺病变中的作用仍鲜为人知。免疫组织化学(IHC)已成为检测乳腺组织中BRAFV600E表达的重要工具,有助于诊断和预后评估。本综述全面探讨了BRAFV600E免疫组化在乳腺病变中的意义,包括其频率、与临床病理特征的关联以及潜在的临床意义。我们总结了关键发现,强调了它们在诊断、预后预测和治疗反应评估中的实用性。此外,我们讨论了对临床实践的影响,强调了将BRAFV600E免疫组化纳入诊断算法的必要性。未来研究的建议包括开展更大规模的研究以验证研究结果、优化检测技术,并探索针对乳腺癌中BRAFV600E的治疗干预措施。本综述有助于了解乳腺病变的分子格局,并为其管理中的临床决策提供参考。